Related Experiment Video

Updated: Jun 17, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Targeting Androgen Receptor Alterations in Metastatic Prostate Cancer

Pawel Rajwa1, Piotr Zapała2, Axel S Merseburger3

  • 1Department of Urology, Medical University of Silesia, Zabrze, Poland; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

European Urology Focus
|August 6, 2024
PubMed

Insights

Advances in metastatic prostate cancer (mPCa) treatment focus on targeting androgen receptor (AR) alterations. Genomic testing identifies AR biomarkers, guiding novel therapies like AR antagonists and inhibitors to overcome treatment resistance.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Metastatic prostate cancer (mPCa) biology and therapeutic responses are increasingly understood.
  • Androgen receptor (AR) alterations are key drivers of treatment resistance in mPCa.

Purpose of the Study:

  • To review recent advances in understanding AR alterations in mPCa.
  • To highlight novel therapeutic strategies targeting AR alterations.
  • To discuss the role of AR alterations as predictive biomarkers.

Main Methods:

  • Genomic testing to detect AR alterations.
  • Review of novel therapeutic agents targeting AR pathways.
  • Analysis of ongoing clinical trials for mPCa treatments.

Main Results:

  • AR alterations are significant predictors of treatment resistance in castration-resistant PCa.
  • Novel therapies targeting AR antagonists, ACK1, AR N-terminal domain, and cytochrome P450 11A1 show promise.
  • Clinical trials investigating AR mutation status are underway.

Conclusions:

  • AR alterations are crucial biomarkers for guiding mPCa treatment strategies.
  • Emerging therapies offer potential to overcome resistance and improve outcomes.
  • Ongoing research and clinical trials may transform mPCa treatment paradigms.
Keywords:
AlterationsAndrogen receptorCastration resistantProstate cancer

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.1K

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
370
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
566